Payment overview · 2025
General Payments
$1,290.85
72 reported records · 20 companies
Healthcare provider profile · identity verified
John Stephen Christensen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND, VA · NPI 1639158066
Verified facts
What the public records show
CMS Open Payments records show John Stephen Christensen, M.D. received $1,290.85 in general payments during 2025 across 72 reported records.
PFIZER INC. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $220.59 | 17.1% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.94 | 11.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.57 | 11.0% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.35 | 8.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.32 | 7.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.14 | 6.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.41 | 5.8% | 5 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $70.24 | 5.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.11 | 4.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.47 | 3.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.37 | 3.9% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $47.72 | 3.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.08 | 1.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.50 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.60 | 1.4% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.55 | 1.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.09 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.90 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.70 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.20 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,290.85 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $143.94 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $124.63 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.83 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.63 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $78.14 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.54 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.41 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.41 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.91 | 5 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $70.24 | 4 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $70.24 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $69.29 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $69.29 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $69.29 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.35 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.84 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.11 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.37 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.91 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.67 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 26 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 850 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 663 | 154 |
| Lisinopril | Lisinopril | 588 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 508 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 506 | 137 |
| Losartan Potassium | Losartan Potassium | 400 | 100 |
| Simvastatin | Simvastatin | 367 | 93 |
| Metformin Hcl | Metformin Hcl | 295 | 76 |
| Sertraline Hcl | Sertraline Hcl | 276 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 266 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 69 |
| Gabapentin | Gabapentin | 236 | 78 |
| Eliquis | Apixaban | 232 | 60 |
| Furosemide | Furosemide | 225 | 61 |
| Potassium Chloride | Potassium Chloride | 225 | 68 |
| Omeprazole | Omeprazole | 220 | 53 |
| Trazodone Hcl | Trazodone Hcl | 208 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 53 |
| Prednisone | Prednisone | 196 | 75 |
| Lorazepam | Lorazepam | 186 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 43 |
| Allopurinol | Allopurinol | 175 | 39 |
| Donepezil Hcl | Donepezil Hcl | 166 | 43 |
| Tramadol Hcl | Tramadol Hcl | 162 | 27 |
| Alprazolam | Alprazolam | 143 | 31 |
| Valsartan | Valsartan | 122 | 32 |
| Metformin Hcl Er | Metformin Hcl | 115 | 26 |
| Montelukast Sodium | Montelukast Sodium | 115 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 22 |
| Alendronate Sodium | Alendronate Sodium | 110 | 29 |
| Synthroid | Levothyroxine Sodium | 99 | 24 |
| Ezetimibe | Ezetimibe | 98 | 22 |
| Cefuroxime | Cefuroxime Axetil | 96 | 47 |
| Famotidine | Famotidine | 92 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 24 |
| Finasteride | Finasteride | 91 | 22 |
| Meloxicam | Meloxicam | 90 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 20 |
| Propranolol Hcl | Propranolol Hcl | 83 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 18 |
| Clonidine Hcl | Clonidine Hcl | 77 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 20 |
| Xarelto | Rivaroxaban | 69 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Glimepiride | Glimepiride | 68 | 17 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | 17 |
| Jardiance | Empagliflozin | 60 | 20 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Azithromycin | Azithromycin | 59 | 55 |
| Bumetanide | Bumetanide | 59 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Atenolol | Atenolol | 52 | 11 |
| Celecoxib | Celecoxib | 51 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 12 |
| Carvedilol | Carvedilol | 50 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 14 |
| Glipizide Er | Glipizide | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 43 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 12 |
| Ozempic | Semaglutide | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 11 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 38 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Spironolactone | Spironolactone | 38 | 13 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 11 |
| Risperidone | Risperidone | 31 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | 11 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 27 | 27 |
| Digoxin | Digoxin | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 11 |
| Linzess | Linaclotide | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 25 |
| Diazepam | Diazepam | 26 | suppressed |
| Klor-Con 10 | Potassium Chloride | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Klor-Con M10 | Potassium Chloride | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Trandolapril | Trandolapril | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,290.85 · 72 records | PFIZER INC. | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, Fluad, Flucelvax, JARDIANCE, JATENZO, KISUNLA, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, THINPREP 2000 PROCESSOR, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error